AbCellera Biologics Inc

NASDAQ:ABCL 4:00:00 PM EDT

3.63

-0.27 (-6.92%)

7:41:36 PM EDT: $3.66 +0.03 (+0.83%)

Market Cap (Intraday)	1.06B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$10.88 Million
Adjusted EPS	-$0.12

See more estimates

10-Day MA	$3.98
50-Day MA	$4.61
200-Day MA	$5.13

See more pivots

AbCellera Biologics Inc Stock, NASDAQ:ABCL

2215 Yukon Street, Vancouver, British Columbia V5Y 0A1

Canada

Phone: +1.604.559.9005

Number of Employees: 586

http://www.abcellera.com

Description

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, VÃ?Â©ronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.